Hostname: page-component-848d4c4894-nr4z6 Total loading time: 0 Render date: 2024-05-11T12:24:20.908Z Has data issue: false hasContentIssue false
  • English
  • Français

Limitations of Long Term Use of Antiparkinson Drugs

Published online by Cambridge University Press:  18 September 2015

Melvin D. Yahr
Melvin D. Yahr*
Affiliation:
Department of Neurology, Mt. Sinai School of Medicine, New York
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Effective control of parkinsonian symptoms can be achieved in a substantial number of patients by the judicious use of dopaminergic agents. To a considerable extent these drugs produce optimal therapeutic effects during the first 3–5 years of their use. Subsequently, efficacy diminishes with reemergence of parkinsonian symptoms as well as a number of untoward responses. The nature, frequency and mechanisms underlying the limitations of long term use of presently available anti-parkinson agents are discussed in this presentation.

Type
7. Treatment of Parkinson’s Disease
Information
Canadian Journal of Neurological Sciences , Volume 11 , Issue S1: Current Concepts and Controversies in Parkinson’s Disease , February 1984 , pp. 191 - 194
Copyright
Copyright © Canadian Neurological Sciences Federation 1984

References

Bauer, RB, Stevens, C, Reveno, WS, Rosenbaum, H (1980) L-Dopa treatment of Parkinson’s Disease: A ten-year follow-up study. J. Amer. Geriat. Soc. 322–326.Google Scholar
Diamond, SG, Markham, CH, Treciokas, LJ (1975) Long-term experience with L-Dopa: Efficacy, progression and mortality. Advances in Parkinsonism, Editiones, Roches, Basle, pp. 444–455.Google Scholar
Hornykiewicz, O (1982) Brain neurotransmitter changes in Parkinson’s disease in Movement Disorders. Edited by Marsden, D. and Fahn, S., Butterworth’s, London, pp. 41–58.Google Scholar
Lee, T, Seeman, TP, Rajput, A, Farley, I, Hornykiewicz, O (1978) Receptor basis for dopaminergic supersensitivity in Parkinson’s disease. Nature. 273 (5657): 59–61.CrossRefGoogle ScholarPubMed
Marsden, CD, Parkes, JD (1977) Success and problems of long-term levodopa therapy in Parkinson’s disease. Lancet: 345–349.CrossRefGoogle Scholar
Sroka, H, Elizan, TS, Yahr, MD, Burger, A, Mendoza, MR (1981) Organic mental syndrome and confusional states in Parkinson’s disease. Arch. Neurol. 38: 339–342.CrossRefGoogle ScholarPubMed
Stern, GM (1981) Current concepts in the Treatment of Parkinson’s disease. Current Concepts of Parkinson’s Disease and Related Disorders: A Symposium. Excerpta Medica. Japan, pp. 145–148.Google Scholar
Yahr, MD (1975) Evaluation of long-term therapy in Parkinson’s disease: Mortality and therapeutic efficacy. Advances in Parkinsonism, Editiones Roches, Basle, pp. 435–444.Google Scholar
Yahr, MD, Clough, CG, Bergmann, KJ (1982) Cholinergic and dopaminergic mechanisms in Parkinson’s disease after long term levodopa administration. Lancet: 709–710.CrossRefGoogle Scholar
Yahr, MD (1977) Long-term levodopa in Parkinson’s disease. Lancet: 986–987.CrossRefGoogle Scholar
Zumstein, H, Siegfried, J (1976) Mortality among parkinson patients treated with L-Dopa combined with a decarboxylase inhibitor. Eur. Neurol. 14: 321–327.CrossRefGoogle ScholarPubMed